040101852026 - ANASTRAZOL 1MG TABLETS

This tender, identified by reference number 040101852026, is for the procurement of Anastrozole 1mg tablets. Anastrozole is a medication used in the treatment of breast cancer, particularly in postmenopausal women, as it belongs to the class of aromatase inhibitors. The primary objective of this procurement is to ensure the availability of this essential medication for patients. Bidders are required to supply high-quality pharmaceutical products that comply with all relevant regulatory standards and specifications. The tender documentation will provide details on the required quantities, packaging, delivery timelines, and quality assurance measures. Interested pharmaceutical manufacturers and distributors are invited to submit their proposals. The evaluation criteria will likely emphasize product quality, reliability of supply, adherence to specifications, and competitive pricing. This acquisition is crucial for supporting breast cancer treatment protocols.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 2,763.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.